## Quality of life in cancer patients treated with mistletoe: a

## systematic review and meta-analysis

5 Martin Loef<sup>3</sup>, Harald Walach<sup>1,2,3\*</sup>

- 9 1) Poznan Medical University, Dept. Pediatric Gastroenterology, Poznan, Poland
- 10 2) Universität Witten-Herdecke, Dept. Psychologie, Witten, Germany
- 11 3) CHS-Institut, Berlin
- \*Address for Correspondence:
- 13 Harald Walach

1

2

3

4

6

7

8

17

- 14 Schönwalder Str. 17
- 15 D 13347 Berlin
- 16 hwalac@gmail.com

**Abstract** 

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

40

42

43

Background: Mistletoe extracts are used as an adjunct therapy for cancer patients, but there is dissent

as to whether this therapy has a positive impact on quality of life (QoL).

Methods: We conducted a systematic review searching in several databases (Medline, Embase,

CENTRAL, CINAHL, PsycInfo, Science Citation Index, clinicaltrials.gov, opengrey.org) by combining

terms that cover the fields of "neoplasm", "quality of life" and "mistletoe". We included prospective

controlled trials that compared mistletoe extracts with a control in cancer patients and reported QoL

or related dimensions. The quality of the studies was assessed with the Cochrane Risk of Bias tool

version 2. We conducted a quantitative meta-analysis.

Results: We included 26 publications with 30 data sets. The studies were heterogeneous. The pooled

standardized mean difference (random effects model) for global QoL after treatment with mistletoe

extracts vs. control was d = 0.61 (95% CI 0.41-0.81; p<0,00001). The effect was stronger for younger

patients, with longer treatment, in studies with lower risk of bias, in randomized and blinded studies.

Sensitivity analyses support the validity of the finding. 50% of the QoL subdomains (e.g. pain, nausea)

show a significant improvement after mistletoe treatment. Most studies have a high risk of bias or at

least raise some concern.

Conclusion: Mistletoe extracts produce a significant, medium-sized effect on QoL in cancer. Risk of bias

in the analyzed studies is likely due to the specific type of treatment, which is difficult to blind; yet this

2

risk is unlikely to affect the outcome.

## Keywords

39 Meta-analysis, quality of life, mistletoe, cancer, systematic review

41 PROSPERO registration number: CRD42019137704

## Background

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

Mistletoe has been used for centuries as a folk remedy, dating back to ancient Greek and Celtic medicine [1, 2]. Today's use of preparations of the European mistletoe (Viscum album L.) in anthroposophic medicine and particularly the treatment of cancer patients has been introduced by Rudolf Steiner (1861-1925) in the 1920s [3] and developed further by Ita Wegmann and various clinicians and pharmacists in this tradition. The basis for this development were, apart from the traditional pharmacopeias, specific anthroposophic investigations involving the phenomenology of mistletoe that grows as a semi-parasite on trees. These and other considerations led Steiner and associates to try mistletoe treatment for cancer. Out of this suggestion a long tradition of empirical knowledge has developed, especially in Germany and Europe. Viscum album extract (VAE) is applied subcutaneously, normally two to three times per week whereas the complete treatment duration varies from some weeks up to five years and more. Different products are available such as ABNOBAViscum, Helixor, Iscador, or Lektinol. Mistletoe contains biologically active molecules including lectins, flavonoides, viscotoxins, oligo- and polysaccharides, alkaloids, membrane lipids and other substances [4]. Although the exact pharmacological mode of action of mistletoe is not completely elucidated, there is a growing number of biological studies with a clear focus on lectins. Lectins (from the Latin legere, "to select") are carbohydrate-binding proteins displayed on cell-surfaces to convey the interaction of cells with their environment [5]. Lectins mediate many immunological activities: For example, lectins show an immunomodulatory effect on neutrophils and macrophages by increasing the natural killer cytotoxicity and the number of activated lymphocytes [6-8]. They induce apoptosis in human lymphocytes [9] and boost the antioxidant system in mice [10]. In healthy subjects, the subcutaneous application of mistletoe has stimulated the production of granulocyte-macrophage colony-stimulating factor (GM-CSF), Interleukin 5 and Interferon gamma [11], indicating the immunopotentiating properties of mistletoe. The multiple ways how mistletoe affects the immune system have been recently reviewed elsewhere [12]. In consequence, the immunological pathways of conventional oncological treatments

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

may be influenced by VAE, affecting cancer cells and decreasing adverse effects. This may result in a better quality of life (QoL). A number of reviews has been published over the last two decades that address the effects of VAE on QoL in cancer patients [13-19]. However, these studies are either out of date, don't make use of all published evidence, and/or don't combine the data quantitatively into a pooled effect size. The aim of this study is therefore to review and analyze the current evidence regarding QoL of cancer patients which were treated with VAE and to calculate a meta-analysis. Methods The study has been reported in accordance to PRISMA. The protocol was submitted to PROSPERO (registration number: CRD42019137704). Sources of evidence We searched the databases Medline, Embase, Psychinfo, CENTRAL, CINAHL, Web of Science, and clinicaltrials.gov, we used google scholar, hand-searched the reference lists of reviews and identified studies and screened for grey literature via Google and opengrey.org. In case of missing data we contacted the authors. **Search strategy** We developed a search strategy by iteratively combining synonyms and/or subterms of "quality of life" (e.g. well-being, QoL), "cancer" (e.g. neoplasm, sarcom, lymphom) and "mistletoe" (e.g. Helixor, Eurixor) to identify an adequate set of terms. We applied the following search strategy for Medline (Pubmed) and adopted it to the other databases accordingly: 1. quality of life OR HRQoL OR HRQL OR QOL OR patient satisfaction OR well-being OR wellbeing 2. mistel OR mistletoe OR Iscador OR Iscar OR Helixor OR Iscucin OR Abnobaviscum OR Eurixor OR Plenosol OR Lektinol OR Vysorel OR Isorel OR Cefalektin OR Viscum

Krebs OR cancer OR neoplasm/ OR tumor OR oncolog\* OR onkologie OR carcin\* OR malignant 96 3. 97 **OR** metastasis 98 4. Humans[MESH] 1 AND 2 AND 3 AND 4 99 5. 100 With the exception of #4 the general search fields were applied. 101 Selection criteria 102 103 We included studies that measured QoL or self-regulation of cancer patients treated with mistletoe 104 extracts assessed by performance status scales or patient-reported instruments. Studies were chosen 105 if they were 106 prospective controlled studies with 107 two or more arms, 108 both interventional and non-interventional. 109 The search was not limited to languages. 110 Studies were excluded if they did not meet the aforementioned inclusion criteria, 111 112 if they tested multi-component complementary medicine interventions, 113 if they failed to report sufficient information to be included into the meta-analysis or 114 where this information cannot be gleaned from authors or extracted from graphs. **Data management** 115 116 The data was extracted from each study and entered into a spreadsheet by two authors independently. 117 Then the extracted spreadsheets were compared and discrepancies were resolved by discussion until 118 consensus was reached. We coded the following characteristics: 119 number of participants in each treatment arm 120 year, when study was conducted; in case this was not given, we estimated a 3 year lag from 121 publication date for the meta-regression

122 duration of study 123 country where the study was conducted 124 cancer type 125 age gender of patients 126 diagnosis according to ICD 10 127 128 duration of study 129 type of study (interventional vs. non-interventional, randomized vs. non-randomized, blinded 130 vs. not blinded, single vs. multi-center) additional therapy (e.g. chemotherapy) 131 132 number of drop-outs in each study arm 133 active mistletoe extract preparation (e.g. Eurixor, Iscador, etc.) control treatment (e.g. placebo) 134 135 effect size of primary outcomes plus standard deviation, or confidence intervals for effect 136 measure provided using the reported global measure of QoL instrument used to measure primary outcomes 137 138 statistics according to intent-to-treat analysis (yes/no) 139 sponsoring of study (corporate, public, no-sponsoring). 140 141 If numerical data provided by the study publication was insufficient to calculate effect sizes, we 142 contacted the authors. In cases where additional data were provided by the authors, these were then 143 used instead of the published data. In older studies this was impossible. In those cases we used the 144 given information (for instance means and confidence intervals, or means and p-values, or statistical 145 information to generate the necessary data). In some cases we had to use medians as means and recover standard errors of the means from the given confidence intervals which also necessitated an 146 147 adaptation of the confidence intervals into symmetrical ones. In each case we used the more conservative option which yielded larger standard errors and hence larger standard deviations. Thus, we generally opted for an error on the conservative side. When no quantitative information was given, but only graphs were presented, we printed high resolution graphs and derived the mean values and standard errors applying a ruler and used the given statistical information to arrive at the necessary quantitative scores. All these procedures were conducted independently and in duplicate [20].

#### Risk of bias (quality) assessment

The Cochrane Risk of Bias tool 2 (Rob 2) was used to assess the risk of bias in randomized controlled trials [21]. All studies were assigned to the intention-to-treat-effect-analysis. Non-randomized or non-interventional studies were additionally analyzed with the Newcastle Ottawa Scale [22]. Two reviewers (HW, ML) independently assessed the risk of bias. In case of discrepancies they decided by consensus.

#### Statistical analysis

The data were analyzed using Comprehensive Meta-Analysis V. 2 and Revman 5.3.5, the summary measure was the standardized mean difference. The meta-analysis was calculated independently by both authors using the two software tools Comprehensive Meta-Analysis and RevMan. The results were compared and underlying discrepancies resolved by discussion until both analyses yielded the same numerical results up to the second decimal. We report the overall analysis according to the results yielded by the RevMan analysis and conducted sensitivity analyses with Comprehensive Meta-Analysis.

The heterogeneity between studies was assessed by the Cochrane Q test and quantified by the index of heterogeneity (I²) [23]. A value of I² of 25%, 50% and 75% indicates low, medium and high heterogeneity, respectively. If heterogeneity was higher than 25% we applied a random effects model for pooling the data, else a fixed effects model was used. As heterogeneity was high for the overall

data-set, a random effects model was indicated. Fixed effect models were only used sparingly in

exploratory subgroup analyses or sensitivity analyses, when heterogeneity was low.

We conducted subgroup analysis in order to identify possible sources of the heterogeneity. Stratified

analyses were performed by: study types (e.g. blinded vs. not blinded, randomized versus non-

randomized, types of control), additional treatments, country, risk-of-bias status, type of sponsoring,

QoL instruments and related dimensions (in particular self-regulation), and mistletoe compound. Type

of cancer was not included, as there were too many different cancer types. We conducted meta-

regressions and regressed the three continuous predictors year of study, age of patients and length of

treatment on effect size. We checked for publication bias using Egger's regression intercept method

and Duval and Tweedie's trim and fill method [24].

### Results

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

598 studies were identified by electronic and hand searches, after removing duplicates. 67 full texts

were retrieved of which 26 publications with 30 separate data sets met the inclusion criteria (see figure

1) [25-50]. We contacted 14 authors for additional information which was granted by five [25, 29, 39,

49, 51].

Insert here: fig. 1

90% of the studies were conducted in Europe including Russia, 50% in Germany, and 10% in Asia. Three

trials were blinded, four studies or datasets were not randomized. Different mistletoe preparations

with varying conventional treatments were compared to conventional treatment (alone in 22 cases or

plus an additional comparator in eight cases, respectively) for multiple types and stages of cancer. In

nine studies QoL was measured with EORTC-QLQ-C30, six studies assessed self-regulation, and the

others used one or multiple other instruments. The study characteristics are displayed in table 1.

199 200 Insert here: tab. 1 201 202 The results of the overall meta-analysis are presented in Figure 2. 203 Insert here: Figure 2. 204 205 206 As can be seen the studies are highly heterogeneous (I<sup>2</sup> = 84%), and hence the random effects model 207 is applied to estimate the combined standardized mean difference as d = 0.61 (95% CI 0.41-0.81, 208 p<0.00001, z=6.05). 209 The meta-analyses of the sub-dimensions of QoL are shown in table 2. The SMD of seven out of 14 QoL 210 dimensions are significant (p≤0.05). The pooled SMD of role and social functioning are 0.63 (95% CI 211 0.05-1.22) and 0.62 (95% CI 0.22-1.03), respectively. For pain, it is SMD=-0.86 (95% CI -1.54-(-0.18)) 212 and for nausea, it is SMD=-0.55 (95% CI -1-(-0.1)). 213 214 215 216 Insert here: tab. 2 217 The risk of bias assessment is displayed in the figures 3 and 4. 65% had an overall high risk of bias which 218 219 resulted for most studies from the 85% high risk of bias in the measurement of outcome. This can be 220 attributed to the missing blinding process, the QoL assessment as patient-reported outcome, and the 221 uncertain appropriateness of some measurement instruments which may only incompletely capture 222 the concept of QoL. 223 224 Insert here: fig. 3

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

The five non-randomized trials [30, 33-35, 42] were additionally assessed with the Newcastle-Ottawascale. All studies had an overall score of 7 out of a maximum of 9. The sums in the selection, the comparability and the outcome/exposure domain were 3, 2 and 2, respectively, for all studies. Insert here: fig. 4 The sensitivity analyses are presented in Table 3. Insert here: tab. 3 The sensitivity analyses confirmed the robustness of the results. Neither the methodological nor other moderator variables showed strong deviations. With the exception of the non-randomized studies (non-randomized: d = 0.38, p = 0.1), the lung cancer studies (d=-0.18, p = 0.15), the studies conducted with Lektinol (d = 0.67, p = 0.1), and the studies using an index measure (e.g. Karnofsky index) as outcome (d = 0.33, p = 0.1) all other moderator analyses showed no appreciable differences between subgroups and yielded highly significant effect sizes. In tendency, methodologically more rigorous studies yielded higher or equally high effect sizes than less rigorous ones. Most notably, randomized studies yielded a higher effect size (d = 0.70, p = 0.001) than non-randomized ones (d = 0.38, p = 0.1). Studies using active controls (d = 0.6, p = 0.004) did not differ from studies using other controls (d = 0.6). 0.65, p < 0.001). Various types of additional treatment did not show differential effect sizes, except individualized best care, which, however, is an estimate based on only one study and hence not reliable. Although the effect sizes of the various products vary, their confidence intervals overlap, and hence suggest the conclusion that they are roughly equally effective. There is no difference in effect

sizes depending on countries, type of sponsoring, or type of measures. Studies that relied on corporate

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

sponsoring, and studies using only a single index measure yielded a somewhat smaller effect size, although confidence intervals overlap and thus signal non-significant differences. The three meta-regressions are presented in Table 4 and in Figures 5 and 6. Insert here: tab. 4 Insert here: fig. 5 The study year is positively correlated with effect size. For each year the study was more recent the estimated QoL-effect size is larger by d = 0.03. Although there is a tendency for a larger effect size in younger patients this effect is not significant. The slope of the regression line for the duration of treatment is borderline significant, indicating that longer treatment produces effects that are 0.04 standard deviations larger per additional treatment week. Note though that only treatments between 5 and 52 weeks have entered the analysis and the variance is not large. Insert here: fig. 6 Publication bias was estimated using two methods. Egger's regression intercept model regresses effect size on precision of study with the assumption that smaller studies that are less precise will more often go unpublished. A regression line with a lot of smaller and more imprecise studies missing should thus miss the origin by a large margin. In our analysis the intercept of the regression is 0.82 with a nonsignificant deviation from the origin (t = 0.65, p-value two tailed = 0.5). Duval and Tweedie's trim and fill method is an extension of the graphical funnel plot analysis and analyzes how many studies would have to be trimmed to generate a perfectly symmetrical funnel plot. In our analysis this method estimates no studies to be trimmed on the left side, i.e on the negative or low side of the effect size estimate and an estimate of 7 trimmed studies on the right side, i.e. on the positive side of the effect size funnel with an adjustment that leads to a higher effect size, if the studies are trimmed. These two analyses of publication bias show that publication bias is not a likely explanation of this result and any funnel asymmetries are not due to unpublished studies but due to positive outliers.

### Discussion

This meta-analysis shows a significant and robust medium-sized effect of d = 0.61 of viscum album

extract (VAE) treatment on QoL in cancer patients.

The results should be regarded in the light of the following facts:

The included studies vary with regard to the cancer site, the control intervention, the additional oncological treatment, and the VAE. While sensitivity analyses confirmed the robustness and reliability of the findings, they could not account for the heterogeneity of the effect sizes. Neither methodological moderators (blinded vs. unblinded studies, randomized versus non-randomized, studies with high versus low risk of bias, active versus non-active control) nor structural moderators (type of outcome measure, funding, VAE product used, additional treatment) could clarify the heterogeneity. We suspect that this is due to multiple interactions between cancer types and stages, treatments and structural variables that cannot be explored with a limited set of 30 studies. Nevertheless, our sensitivity analyses document the overall robustness of the effect, as none of the

This gives our effect size estimate of d = 0.61 reliability.

Although the overall risk of bias is high in many studies, one should bear in mind two aspects. First, we applied the intention-to-treat-algorithm of Rob2 as the more conservative approach and not the perprotocol evaluation which may have resulted in a better overall bias. Second, due to the local skin

levels of moderators exhibits significant deviations from other levels or from the overall effect size.

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

reaction of VAE application the blinding of participants and carers is practically impossible and could only have been implemented reliably with an active placebo, which is ethically questionable. In Rob2 this leads to a high risk of bias in the measurement of the outcome. On the one hand, the lack of blinding might have biased the results since most QoL are self-reported and there may be strong beliefs among users of anthroposophic medicine which might additionally be fortified by the severity of the disease and the hope that an additional treatment has a positive impact [52]. It was shown that these attitudes are correlated with a better QoL [53]. On the other hand, there is no evidence from the included studies that the attitudes differed between treatment arms and if patients in the control group searched and used for surrogate medications for the VAE, this bias would favor the comparator. Furthermore, our sensitivity analysis gives no indication that studies with blinding and without blinding estimate different effect sizes and there is also no difference in effect sizes between studies from Germany – where mistletoe is well known – and other countries where mistletoe is less known and used. The results of the Newcastle-Ottawa-Scale, finally, indicate a good methodological quality for the non-randomized trials that were included in the review. Another limitation is that self-regulation, the Karnofsky performance index, or the ECOG scale cover important aspects of QoL, but are different in content from other measures such as the global QoL of the EORTC-QLQ C30 scale. This source of heterogeneity was also addressed by our sensitivity analyses. This showed that, indeed, as one would expect, single item indices estimate lower effect sizes, although the difference is not significant. In the same vein, the inclusion of non-randomized and noninterventional trials might have biased the results due to their lower internal validity, but their exclusion during sensitivity analyses again did not alter the significance of the pooled outcome. In addition, four of the five non-RCTs had a matched-pair design which increases the comparability between treatment arms compared to other types of group allocation. The meta-regression shows that more recent studies have higher effect sizes compared to older studies. This is counterintuitive at first sight, as normally more recent studies are implemented with

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

more methodological rigor due to the GCP guidelines and a higher methodological skill of trialists. This, one would think, should, if at all, lead to smaller effect sizes in more recent trials. The fact that this is not the case shows, together with our sensitivity analysis that methodological bias is an unlikely explanation for the effect size found. However, another point is worth bearing in mind: earlier studies were very often implemented with severely ill patients with tumor status IV or in palliative care. Only in more recent studies was VAE also used as add on treatment in first line patients with a relatively good chance of surviving. Thus the higher effect size for more recent studies might also reflect the less severe status of these patients. Our review has a number of strengths. First, we conducted a comprehensive search for published and grey literature with no time or language limitation to minimize publication bias. Our analysis of publication bias supports the conclusion that the effect size estimate is not due to publication bias. Some authors who we contacted, however, failed to provide additional information and the respective studies were consequently excluded. Second, we calculated a pooled SMD for a global measure of QoL and for its subdomains such as pain or fatigue. Third, we analyzed the data both with Revman 5.3 and CMA software which implements the Hunter-Schmidt-corrections for small sample bias. We did both analyses in parallel and independently, thus preventing coding or typing errors from biasing our results. The weaknesses of this review are obvious. Any meta-analysis can only be as good as the original studies entered. Some of these studies are large and methodologically strong. But some are also badly reported, small and with a mixed patient load. In some cases we had to recalibrate confidence interval estimates, because the data given were not detailed enough. Although it would have been desirable, the variance between cancer types and stages was too large to allow for detailed assessments and separate analyses, which might have reduced the heterogeneity. Although we can testify to the robustness of the overall effect size estimate, we have not succeeded in clarifying the heterogeneity of the studies. This requires multi-center studies in large cohorts of patients with large budgets. Thus,

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

one consequence of this meta-analysis would be to call for more serious efforts from public funders to study the effects of VAEs in large and homogeneous patient cohorts to confirm or disconfirm the results of this analysis. Clinical relevance Our results indicate a statistically significant and clinically valuable improvement of the subjective wellbeing of patients with different types of cancer after the treatment with VAE. The analyses for the subdomains revealed a significant pooled SMD for important symptoms and functioning indices, whereas other show a positive, yet not significant effect of VAE compared to control. Whether these vital elements of QoL such as emotional functioning or fatigue are influenced remain statistically uncertain. Overall, a robust estimate of an improvement of d = 0.61 in quality of life represents a medium-sized [54] and clinically relevant [55, 56] effect that makes VAE treatment a viable add-on option to any anticancer treatment. Conclusion Our analysis provides evidence that global QoL in cancer patients is positively influenced by VAE. Because the risk of bias and the heterogeneity is high, future research needs to better assess the actual impact. Large studies in homogeneous patient populations are required to address these problems. **Declarations** Ethics Approval and Consent to Participate Not applicable Consent for Publication

379 Not applicable Availability of Data and Materials 380 381 The database on which this study is based is available on request from the authors. **Competing Interests** 382 383 The authors have no conflict of interest to declare. **Funding** 384 385 This study was funded by the Förderverein komplementärmedizinische Forschung, Arlesheim, Switzerland. 386 Authors' Contributions 387 388 Both authors contributed equally. HW developed the protocol, ML edited and improved it and 389 submitted it to PROSPERO. ML developed and implemented the search strategy. Both authors 390 extracted the data independently, discussed discrepancies, and calculated the analyses 391 independently. ML calculated the quantitative analysis reported and HW calculated the sensitivity 392 analyses reported. ML wrote the first draft of the paper and HW edited and contributed to writing. 393 Both authors analyzed and interpreted the data. All authors have read and approved the manuscript. Acknowledgment 394 Not applicable 395 Author's information 396 397 Harald Walach is a professor with Poznan Medical University, where he teaches mindfulness to the 398 international medical students, and he is a visiting professor with University Witten-Herdecke, where 399 he teaches philosophical foundations of psychology to psychology undergraduates. Apart from that 400 he is founder and director of the Change Health Science Institute (www.chs-institute.org), based in

Berlin Germany. Martin Loef is an independent researcher and Harald Walach's partner in the CHS Institute, Berlin. He is a specialist in conducting systematic reviews and meta-analyses and lifestyle diagnostics.

## References

407

- 409 1. Fornaro M, Clementi N, Fornaro P. Medicine and psychiatry in Western culture: Ancient
- 410 Greek myths and modern prejudices. Annals of General Psychiatry. 2009;8(1):21.
- 411 2. Riddle JM. Folk tradition and folk medicine: recognition of drugs in classical antiquity.
- 412 Pharmacy in history. 2013;55(2/3):64-87.
- 413 3. Steiner R. Geisteswissenschaft und Medizin: zwanzig Vorträge, gehalten in Dornach vom 21.
- 414 März bis 9. April 1920 vor Ärzten und Medizinstudierenden: Rudolf-Steiner-Verlag; 1985.
- 415 4. Pfüller U. Chemical Constituents of European Mistletoe (Viscum album L.) Isolation and
- Characterisation of the Main Relevant Ingredients: Lectins, Viscotoxins, Oligo-/polysaccharides,
- 417 Flavonoides, Alkaloids. Mistletoe: CRC Press; 2003. p. 117-38.
- 418 5. Berg JM, Tymoczko JL, Stryer L. Biochemistry/Jeremy M. Berg, John L. Tymoczko, Lubert
- 419 Stryer; with Gregory J. Gatto, Jr. New York: WH Freeman; 2012.
- 420 6. Hoessli DC, Ahmad I. Mistletoe lectins: carbohydrate-specific apoptosis inducers and
- 421 immunomodulators. Current Organic Chemistry. 2008;12(11):918-25.
- 422 7. Hajto T, Hostanska K, Gabius H-J. Modulatory potency of the β-galactoside-specific lectin
- from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. Cancer
- 424 Research. 1989;49(17):4803-8.
- 425 8. Hülsen H, Born U. Einfluss von Mistelpräparaten auf die In-vitro-Aktivität der natürlichen
- 426 Killerzellen von Krebspatienten (Teil 2). Therapeutikon. 1993;7(10):434-9.
- 9. Büssing A, Suzart K, Bergmann J, Pfüller U, Schietzel M, Schweizer K. Induction of apoptosis in
- 428 human lymphocytes treated with Viscum album L. is mediated by the mistletoe lectins. Cancer
- 429 letters. 1996;99(1):59-72.
- 430 10. Greń A, Formicki G, Massanyi P, Szaroma W, Lukáč N, Kapusta E. Use of Iscador, an extract of
- 431 mistletoe (Viscum album L.) in treatment. Journal of Microbiology, Biotechnology and Food Sciences.
- 432 2019;2019:19-20.
- 433 11. Huber R, Rostock M, Goedl R, Ludtke R, Urech K, Buck S, Klein R. Mistletoe treatment induces
- 434 GM-CSF-and IL-5 production by PBMC and increases blood granulocyte-and eosinophil counts: a
- 435 placebo controlled randomized study in healthy subjects. European journal of medical research.
- 436 2005;10(10):411.
- 437 12. Oei SL, Thronicke A, Schad F. Mistletoe and Immunomodulation: Insights and Implications for
- 438 Anticancer Therapies. Evidence-Based Complementary and Alternative Medicine. 2019;2019.
- 439 13. Büssing A, Raak C, Ostermann T. Quality of life and related dimensions in cancer patients
- 440 treated with mistletoe extract (iscador): a meta-analysis. Evidence-Based Complementary and
- 441 Alternative Medicine. 2012;2012.
- 442 14. Ernst E, Schmidt K, Steuer-Vogt MK. Mistletoe for cancer? A systematic review of randomised
- clinical trials. International journal of cancer. [Journal: Review]. 2003;107(2):262-7.
- 444 15. Freuding M, Keinki C, Kutschan S, Micke O, Buentzel J, Huebner J. Mistletoe in oncological
- treatment: a systematic review: Part 2: quality of life and toxicity of cancer treatment. Journal of
- 446 cancer research and clinical oncology. 2019b.
- 447 16. Freuding M, Keinki C, Micke O, Buentzel J, Huebner J. Mistletoe in oncological treatment: a
- 448 systematic review. Journal of cancer research and clinical oncology. 2019a;145(3):695-707.
- 449 17. Horneber M, Bueschel G, Huber R, Linde K, Rostock M. Mistletoe therapy in oncology.
- 450 Cochrane Database of Systematic Reviews. 2008(2).
- 451 18. Kienle GS, Kiene H. Influence of Viscum album L (European mistletoe) extracts on quality of
- 452 life in cancer patients: a systematic review of controlled clinical studies. Integrative cancer therapies.
- 453 2010;9(2):142-57.
- 454 19. Melzer J, Iten F, Hostanska K, Saller R. Efficacy and safety of mistletoe preparations (Viscum
- album) for patients with cancer diseases. Complementary Medicine Research. 2009;16(4):217-26.

- 456 20. Higgins JPT, Thomas J, Chandler J, Cumpston M LT, Page MJ, VA W, editors. Cochrane
- 457 Handbook for Systematic Reviews of Interventions Version 6: The Cochrane Collaboration; 2019.
- 458 21. Cochrane. RoB 2: A revised Cochrane risk-of-bias tool for randomized trials. 2019
- 459 [17.05.2019]; Available from: https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-
- 460 risk-bias-tool-randomized-trials.
- 461 22. Wells G. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non randomised
- studies in meta-analyses. <a href="http://wwwohrica/programs/clinical\_epidemiology/oxfordasp">http://wwwohrica/programs/clinical\_epidemiology/oxfordasp</a>. 2001.
- 463 23. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in
- 464 medicine. 2002;21(11):1539-58.
- 465 24. Sterne JA, Egger M. Regression methods to detect publication and other bias in meta-
- analysis. Publication bias in meta-analysis: Prevention, assessment and adjustments. 2005:99-110.
- 467 25. Bar-Sela G, Wollner M, Hammer L, Agbarya A, Dudnik E, Haim N. Mistletoe as complementary
- treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based
- combinations: a randomised phase II study. Eur J Cancer. 2013;49(5):1058-64.
- 470 26. Borrelli E. Evaluation of the quality of life in breast cancer patients undergoing lectin
- 471 standardized mistletoe therapy. Minerva medica. 2001;92(Suppl 1 Nr 3):105-7.
- 472 27. Dold ULE, H. Ch. Mäurer, D. Müller-Wening, B. Sakellariou, F. Trendelenburg, G. Wagner, .
- 473 Krebszusatztherapie beim fortgeschrittenen nicht-kleinzelligen Bronchialkarzinom. Stuttgart-New
- 474 York: Georg Thieme Verlag; 1991.
- 475 28. Enesel MB, Acalovschi I, Grosu V, Sbarcea A, Rusu C, Dobre A, Weiss T, ZARKOVIC N.
- 476 Perioperative application of the Viscum album extract Isorel in digestive tract cancer patients.
- 477 Anticancer research. 2005;25(6C):4583-90.
- 478 29. Grah C. Misteltherapie bei nichtkleinzelligem Bronchialkarzinom. Berlin: Fu-Berlin; 2010.
- 479 30. Grossarth-Maticek R, Ziegler R. Prospective controlled cohort studies on long-term therapy of
- breast cancer patients with a mistletoe preparation (Iscador®). Complementary Medicine Research.
- 481 2006a;13(5):285-92.
- 482 31. Grossarth-Maticek R, Ziegler R. Randomised and non-randomised prospective controlled
- 483 cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a
- 484 mistletoe preparation (Iscador): a re-analysis. European journal of medical research.
- 485 2006b;11(11):485.
- 486 32. Grossarth-Maticek R, Ziegler R. Efficacy and safety of the long-term treatment of melanoma
- 487 with a mistletoe preparation (Iscador). SCHWEIZERISCHE ZEITSCHRIFT FUR GANZHEITS MEDIZIN.
- 488 2007c;19(6):325.
- 489 33. Grossarth-Maticek R, Ziegler R. Prospective controlled cohort studies on long-term therapy of
- 490 ovarian cancer patients with mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung.
- 491 2007b;57(10):665-78.
- 492 34. Grossarth-Maticek R, Ziegler R. Prospective controlled cohort studies on long-term therapy of
- 493 cervical cancer patients with a mistletoe preparation (Iscador®). Complementary Medicine Research.
- 494 2007a;14(3):140-7.
- 495 35. Grossarth-Maticek R, Ziegler R. Randomized and non-randomized prospective controlled
- cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with
- 497 a mistletoe preparation (Iscador). European journal of medical research. 2008;13(3):107.
- 498 36. Heiny B. Additive Therapie mit standardisiertem Mistelextrakt reduziert die Leukopenie und
- 499 verbessert die Lebensqualität von Patientinnen mit fortgeschrittenem Mammakarzinom unter
- palliativer Chemotherapie (VEC-Schema). Krebsmedizin. 1991;12:1-14.
- 37. Heiny BM, Albrecht V, Beuth J. Stabilization of the quality of life by mistletoe lectin-1
- standardized mistletoe extract in advanced colorectal carcinoma. Onkologe. [Journal: Short Survey].
- 503 1998;4(SUPPL. 1):S35-S8.
- 38. Kaiser G, Büschel M, Horneber M, Smetak M, Birkmann J, Braun W, Fischer S, Laue Hv, Scheer
- 505 R, Gallmaier W. Studiendesign und erste Ergebnisse einer prospektiven placebokontrollierten,
- 506 randomisierten Studie mit AbnobaViscum Mali 4. Die Mistel in der Tumortherapie
- 507 Grundlagenforschung und Klinik: KVC publisher; 2001. p. 485-505.


- 508 39. Kim KC, Yook JH, Eisenbraun J, Kim BS, Huber R. Quality of life, immunomodulation and safety
- of adjuvant mistletoe treatment in patients with gastric carcinoma a randomized, controlled pilot
- 510 study. BMC Complement Altern Med. 2012;12(172):1472-6882.
- 511 40. Lange O, Scholz G, Gutsch J. Modulation of the subjective and objective toxicity of an
- 512 aggressive chemoradiotherapy with Helixor [Modulation der subjektiven und objektiven Toxizität
- 513 einer aggressiven Chemo/Radiotherapie mit Helixor]. Helixor. 1988:unpublished manuscript.
- 514 41. Lenartz D, Stoffel B, Menzel J, Beuth J. Immunoprotective activity of the galactoside-specific
- lectin from mistletoe after tumor destructive therapy in glioma patients. Anticancer research.
- 516 1996;16(6B):3799-802.
- 517 42. Loewe-Mesch A, Kuehn J, Borho K, Abel U, Bauer C, Gerhard I, Schneeweiss A, Sohn C,
- 518 Strowitzki T, Von Hagens C. Adjuvante simultane Mistel-/Chemotherapie bei Mammakarzinom-
- 519 Einfluss auf Immunparameter, Lebensqualität und Verträglichkeit. Complementary Medicine
- 520 Research. 2008;15(1):22-30.
- 521 43. Longhi A, Mariani E, Kuehn JJ. A randomized study with adjuvant mistletoe versus oral
- 522 Etoposide on post relapse disease-free survival in osteosarcoma patients. European journal of
- 523 integrative medicine. 2009;1(1):31-9.
- 524 44. Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth J, Lin HS. Impact of
- 525 complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell
- 526 lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res.
- 527 2004;24(1):303-9
- 528 45. Semiglasov VF, Stepula VV, Dudov A, Lehmacher W, Mengs U. The standardised mistletoe
- 529 extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a
- randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer research. [Clinical
- Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S.
- 532 Gov't]. 2004;24(2C):1293-302.
- 533 46. Semiglazov VF, Stepula VV, Dudov A, Schnitker J, Mengs U. Quality of life is improved in
- 534 breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-
- up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res.
- 536 2006;26(2B):1519-29.
- 537 47. Steuer-Vogt M, Bonkowsky V, Scholz M, Fauser C, Licht K, Ambrosch P. Influence of ML-1
- 538 standardized mistletoe extract on the quality of life in head and neck cancer patients. Hno.
- 539 2006;54(4):277-86.
- 540 48. Troger W, Jezdic S, Zdrale Z, Tisma N, Hamre HJ, Matijasevic M. Quality of life and
- neutropenia in patients with early stage breast cancer: a randomized pilot study comparing
- additional treatment with mistletoe extract to chemotherapy alone. Breast cancer: basic and clinical
- research. [Journal: Article]. 2009;3(1):35-45.
- 544 49. Tröger W, Zdrale Z, Tisma N, Matijasevic M. Additional therapy with a mistletoe product
- during adjuvant chemotherapy of breast cancer patients improves quality of life: an open
- randomized clinical pilot trial. Evidence-Based Complementary and Alternative Medicine. [Journal:
- 547 Article]. 2014a;2014.
- 548 50. Tröger W, Galun D, Reif M, Schumann A, Stanković N, Milićević M. Quality of life of patients
- 549 with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial.
- 550 Deutsches Ärzteblatt International. [Clinical Trial, Phase III; Journal Article; Randomized Controlled
- 551 Trial]. 2014b;111(29-30):493-502, 33 p following
- 552 51. Tröger W, Galun D, Reif M, Schumann A, Stankovic N, Milicevic M. Quality of life of patients
- with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial.
- 554 Deutsches Ärzteblatt International. 2014;111(29-30):493.
- 555 52. von Rohr E, Pampallona S, van Wegberg B, Cerny T, Hürny C, Bernhard J, Helwig S, Heusser P.
- 556 Attitudes and beliefs towards disease and treatment in patients with advanced cancer using
- anthroposophical medicine. Oncology research and treatment. 2000;23(6):558-63.
- 558 53. Beadle GF, Yates P, Najman JM, Clavarino A, Thomson D, Williams G, Kenny L, Roberts S,
- Mason B, Schlect D. Illusions in advanced cancer: the effect of belief systems and attitudes on quality

- of life. Psycho-Oncology: Journal of the Psychological, Social and Behavioral Dimensions of Cancer.
- 561 2004;13(1):26-36.

575


- 562 54. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence
- 563 Erlbaum Associates, Publishers; 1988.
- 55. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in
- health-related quality-of-life scores. Journal of clinical oncology. 1998;16(1):139-44.
- 566 56. Cella D, Eton DT, Fairclough DL, Bonomi P, Heyes AE, Silberman C, Wolf MK, Johnson DH.
- What is a clinically meaningful change on the Functional Assessment of Cancer Therapy–Lung (FACT-
- L) questionnaire?: Results from eastern cooperative oncology group (ECOG) study 5592. Journal of
- 569 clinical epidemiology. 2002;55(3):285-95.
- 570 57. Longhi A, Reif M, Mariani E, Ferrari S. A randomized study on postrelapse disease-free
- 571 survival with adjuvant mistletoe versus oral etoposide in osteosarcoma patients. Evidence-Based
- 572 Complementary and Alternative Medicine. 2014;2014.

List of figure and table legends Fig. 1: Flow of literature search process Fig. 2: Overall Meta-analysis of all included data sets Fig. 3: Summary of risk of bias assessment as percentage (intention-to-treat) Fig. 4: Risk of bias assessment by domain and overall bias Fig. 5: Scatterplot of the meta-regression of study year on effect-size Fig. 6: Scatterplot of the meta-regression of treatment duration on effect size Tab. 1: Characteristics of included studies Tab. 2: Effect sizes of sub-dimensions of QoL that could be pooled by meta-analyses (positive [negative] values in functioning [symptom] dimensions indicate improvement for VAE vs. control) Table 3: Sensitivity analyses according to various moderators Table 4: Meta-regression results




\*e.g. not human, ongoing trials, finished trials without reports, results published multiple times

	9	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Bar-Sela 2013	3.3%	-0.17 [-0.70, 0.36]	<del></del>
Borrelli 2001	2.6%	0.40 [-0.37, 1.16]	+
Dold 1991	3.9%	-0.09 [-0.39, 0.21]	<del>-</del>
Enesel 2005	3.4%	0.77 [0.28, 1.27]	<del></del>
Grah 2010	3.2%	-0.50 [-1.07, 0.07]	<del></del>
Grossarth-Maticek 2006a1	3.5%	0.52 [0.06, 0.98]	<del></del>
Grossarth-Maticek 2006a2	3.9%	0.30 [-0.00, 0.61]	<del> </del>
Grossarth-Maticek 2006b	2.8%	0.66 [-0.04, 1.35]	<del></del>
Grossarth-Maticek 2007a1	4.0%	0.68 [0.40, 0.97]	-
Grossarth-Maticek 2007a2	2.9%	0.79 [0.13, 1.46]	<del></del>
Grossarth-Maticek 2007b1	3.9%	0.48 [0.15, 0.81]	
Grossarth-Maticek 2007b2	2.9%	1.23 [0.56, 1.89]	<del></del>
Grossarth-Maticek 2007c	3.1%	0.80 [0.18, 1.41]	<del></del>
Grossarth-Maticek 2008-1	4.0%	0.71 [0.43, 0.99]	-
Grossarth-Maticek 2008-2	3.3%	0.80 [0.27, 1.33]	<del></del>
Heiny 1991	3.0%	0.83 [0.18, 1.48]	<del></del>
Heiny 1997	3.2%	2.17 [1.61, 2.73]	_ <del>-</del>
Kaiser 2001	2.3%	1.17 [0.29, 2.05]	<del></del>
Kim 2012	2.7%	0.25 [-0.48, 0.98]	<del></del>
Lange 1988	3.1%	0.44 [-0.16, 1.04]	<del> </del>
Lenartz 1996	2.6%	0.26 [-0.51, 1.03]	<del></del>
Loewe-Mesch 2008	3.4%	-0.13 [-0.61, 0.36]	<del></del>
Longhi 2014	2.3%	0.68 [-0.23, 1.59]	<del> </del>
Piao 2004	4.0%	0.25 [-0.01, 0.52]	<del>-</del>
Semiglasov 2004	3.8%	0.50 [0.16, 0.85]	
Semiglazov 2006	4.1%	0.82 [0.60, 1.05]	-
Steuer-Vogt 2005	4.1%	0.57 [0.33, 0.82]	-
Troeger 2009	3.4%	0.29 [-0.22, 0.79]	<del> </del>
Troeger 2014a	3.4%	0.59 [0.08, 1.11]	
Troeger 2014b	3.7%	2.34 [1.94, 2.73]	_ <del>-</del>
Total (95% CI)	100.0%	0.61 [0.41, 0.81]	◆
Heterogeneity: Tau² = 0.24; (	Chi <sup>z</sup> = 181.3	77, df = 29 (P < 0.00001);	= 84% -4 -2 0 2 4
Test for overall effect: Z = 6.0	00 (P < 0.00	001)	-4 -2 U 2 4 Favours [control] Favours [mistletoe]



		Randomization process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall Bias
Trial ID	Outcome	- Ra	<u>.</u> . ⊑	Σ	Σ	Se	б (!)
Bar-Sela_2013	EORTC-QLQ-C30	?	?	×		?	•
Borrelli_2001	Spitzer QoL			•			
Dold_1991	Karnofsky index	-	?	?		•	
Enesel_2005	Karnofsky index	?	3	<b>T</b>		?	
Grah_2010	EORTC-QLQ C30	•	?	•		•	<u>'</u>
Grossarth-Maticek_2006a	self-regulation	•	?	•		•	
Grossarth-Maticek_2006b	self-regulation	•	?	•			
Grossarth-Maticek_2007a	self-regulation	•	3	•			
Grossarth-Maticek_2007b	self-regulation	•	?	•			
Grossarth-Maticek_2007c	self-regulation	•	?	•	•	?	
Grossarth-Maticek_2008	self-regulation	+	?	•	•		
Heiny_1991	5-point scale	?		?		?	
Heiny_1997	FACT	?	?	0		?	
Kaiser_2001	ECOG	3	•				
Kim_2012	EORTC-QLQ-C30	+	?	+		<b>(+)</b>	(!)
Lange_1988	Karnofsky Index	?	3			?	
Lenartz_1996	Spitzer QoL	?				?	
Loewe-Mesch_2008	EORTC-QLQ-C30		?			?	
Longhi_2014	EORTC-QLQ-C30	•	?	•		•	(!)
Piao_2004	FLIC	?	?	•			
Semiglasov_2004	GLQ-8	+	+	•	+		!
Semiglazov_2006	FACT	•	+	+	+	?	+
Steuer-Vogt_2006	EORTC-QLQ-C30	4	?	•		?	
Troeger_2009	EORTC-QLQ-C30	+	?	•		?	
Troeger_2014a	EORTC-QLQ-C30	+	?	•		+	!
Troeger_2014b	EORTC-QLQ-C30	+	?	•		0	!

## Regression of Year on Std diff in means




628

629

630

# Regression of Duration on Std diff in means



Tab. 1

			Participants (nun	nber at baseline;				
			number of fema	ales; mean age)		Interve	ention	QoL
Reference	Country	Study type	verum	control	Cancer, stage	verum	control	measurement
					lung cancer			
		single-center, randomized, 2 arms,			(NSCLC), IIIa, IIIb,	chemotherapy,		
Bar-Sela 2013	Israel	unblinded, interventional	33; 5; 63	39; 11; 62	IV	Iscador Q	chemotherapy	EORTC-QLQ-C30
						surgery/	surgery/	
		randomized, 2 arms, unblinded,				chemotherapy, then	chemotherapy,	
Borrelli 2001	Italy*	interventional	20; 20; n/a	10; 10; n/a	breast cancer, IV	mistletoe extract	then water	Spitzer QoL
							conventional	
						conventional	oncological	
		multi-center, randomized, 2 arms,			lung cancer	oncological therapy,	therapy, BVK	
Dold 1991	Germany	unblinded, interventional	114; 6; 65,6	113; 6; 67,5	(NSCLC), I-IV	Iscador Q	Roche	KPI
		randomized, 2 arms, unblinded,			digestive tract			
Enesel 2005	Romania*	interventional	40; n/a; n/a	30; n/a; n/a	cancer, n/a	surgery, Isorel A	surgery	KPI
		single-center, randomized, 2 arms,			lung cancer	chemotherapy,		
Grah 2010	Germany	unblinded, interventional	26; 7; 64,3	24; 7; 63	(NSCLC), IIIb, IV	Iscador Q spezial	chemotherapy	EORTC-QLQ-C30

		multi-center, multiple data-sets,	MammaRand: 39;	MammaRand: 39;				
		randomized/ not randomized, 2 arms,	39; 52,8	39; 52,9		conventional	conventional	
Grossarth-		unblinded, interventional/not	Mamma: 97; 97;	Mamma: 97; 97;	breast cancer,	oncological therapy,	oncological	
Maticek, 2006a	Germany	interventional, nested matched pairs	52,2	52,2	T1a-T3	Iscador	therapy	self-regulation
		multi-center, randomized, 2 arms,				conventional	conventional	
Grossarth-		unblinded, interventional, nested			breast cancer, T2-	oncological therapy,	oncological	
Maticek, 2006b	Germany	matched pairs	17; 17; 44,5	17; 17; 44,6	4	Iscador	therapy	self-regulation
		multi-center, multiple data-sets,	Cervix: 102; 102;	Cervix: 102; 102;				
		randomized/ not randomized, 2 arms,	51	51		conventional	conventional	
Grossarth-		unblinded, interventional/not	CervixMetRand:	CervixMetRand:	cervical cancer,	oncological therapy,	oncological	
Maticek, 2007a	Germany	interventional, nested matched pairs	19; 19; 47,7	19; 19; 47,6	IB-IVa	Iscador	therapy	self-regulation
		multi-center, multiple data-sets,						
		randomized/ not randomized, 2 arms,	Ovar: 75; 75; 43	Ovar: 75; 75; 45,1		conventional	conventional	
Grossarth-		unblinded, interventional/not	OvarRand: 21; 21;	OvarRand: 21; 21;	ovarian cancer,	oncological therapy,	oncological	
Maticek, 2007b	Germany	interventional, nested matched pairs	45,4	45,5	IA-C, IV	Iscador	therapy	self-regulation
		multi-center, randomized, 2 arms,				conventional	conventional	
Grossarth-		unblinded, interventional, nested				oncological therapy,	oncological	
Maticek, 2007c	Germany	matched pairs	22; 8; 52	22; 8; 52	melanoma, n/a	Iscador	therapy	self-regulation

		multi-center, multiple data-sets,	Corpus: 105; 105;	Corpus: 105; 105;				
		randomized/ not randomized, 2 arms,	58,5	59,1	corpus uteri	conventional	conventional	
Grossarth-		unblinded, interventional/not	CorpusRand: 31;	CorpusRand: 31;	cancer, IA-C, IIIa-	oncological therapy,	oncological	
Maticek, 2008	Germany	interventional, nested matched pairs	31; 55,1	31; 55,1	IVb	Iscador	therapy	self-regulation
							chemotherapy,	QoL scale based
		randomized, 2 arms, unblinded,			breast cancer,	chemotherapy,	infusion of saline	on FLIC, self-
Heiny 1991	Germany*	interventional	25; 25; n/a	21; 21; n/a	advanced	Eurixor	solution	assessment
		randomized, 2 arms, unblinded,			colorectal cancer,	chemotherapy,		
Heiny 1997/1998	Germany*	interventional	38; 16; 54,7	41; 18; 53,2	advanced	Eurixor	chemotherapy	FACT-G
		randomized, 2 arms, blinded,	29; 15; n/a in	29; 15; n/a in	multiple cancer,	n/a, AbnobaVISCUM		
Kaiser 2001	Germany*	interventional, cross-over	both arms	both arms	n/a	Mali 4	n/a, isotone puffer	ECOG
						waiting for		
		single-center, randomized, 2 arms,			gastric cancer, lb,	chemotherapy,	waiting for	
Kim 2012	South Korea	unblinded, interventional	16; 3; 53,8	16; 3; 54,9	П	AbnobaVISCUM Q	chemotherapy	EORTC-QLQ-C30
						conventional	conventional	
		single-center, randomized, 2 arms,			multiple cancer,	oncological therapy,	oncological	
Lange 1988	Germany	unblinded, interventional	35; 9; 58,3	33; 9; 60,2	n/a	Helixor A	therapy	КРІ
						conventional	conventional	
		randomized, 2 arms, unblinded,				oncological therapy,	oncological	
Lenartz 1996	Germany*	interventional	18; 6; 52	17; 7; 52	glioma, III-IV	mistletoe extract	therapy	Spitzer QoL

Loewe-Mesch		single-center, not randomized, 2 arms,			breast cancer,	chemotherapy,		
2008	Germany	unblinded, interventional	39; 39; 47,5	43; 43; 47,5	Tla-c, Tll	Iscador M spezial	chemotherapy	EORTC-QLQ-C30
		single-center, randomized, 2 arms,			osteosarcoma, IB-			
Longhi 2014	Italy	unblinded, interventional	9; 5; 28	11; 4; 39	IIIB	Iscador P	Etoposide (oral)	EORTC-QLQ-C30
		multi-center, randomized, 2 arms,			multiple cancer,	chemotherapy,	chemotherapy,	
Piao 2004	China	unblinded, interventional	118; 91; 52,6	115; 91; 51,7	pTx, pT1-4	Helixor	Lentinan (i.m.)	TCM, FLIC, KPI
	Bulgaria,							
	Russia,	multi-center, randomized, 4 arms,			breast cancer,	chemotherapy,	chemotherapy,	GLQ-8, Spitzer
Semiglasov 2004	Ukraine	blinded, interventional	67; 67; 44,6	70; 70; 43,5	pT1-3	Lektinol (PS76A)	placebo	uniscale
	Bulgaria,							
	Russia,	multi-center, randomized, 2 arms,			breast cancer,	chemotherapy,	chemotherapy,	FACT-G, GLQ-8,
Semiglazov 2006	Ukraine	blinded, interventional	176; 176; 46,4	176; 176; 45,9	pTis-pT3	Lektinol (PS76A)	placebo	Spitzer uniscale
		multi-center, randomized, 2 arms,			head neck cancer,			
Steuer-Vogt 2006	Germany	unblinded, interventional	200; 17; 55	199; 14; 55	I-IV	surgery, Eurixor	surgery	EORTC-QLQ-C30
		single-center, randomized, 2 arms,			breast cancer, Tx,	chemotherapy,		
Tröger 2009	Serbia	unblinded, interventional	30; 30; 48,4	31; 31; 50,8	T1-3	Iscador M spezial	chemotherapy	EORTC-QLQ-C30
		single-center, randomized, 2 arms,			breast cancer, Tx,	chemotherapy,		
Tröger 2014a	Serbia	unblinded, interventional	34; 34; 50,4	31; 31; 50,8	T1-3	Helixor	chemotherapy	EORTC-QLQ-C30
		single-center, randomized, 2 arms,			pancreatic cancer,	supportive care,		
Tröger 2014b	Serbia	unblinded, interventional	110; 45; 62,2	110; 47; 64,4	T3-T4	Iscador Q	supportive care	EORTC-QLQ-C30

\* not explicitely reported

Table 2

Dimension	Included studies	# of patients	SMD	95% CI	p value
Physical functioning	[25, 29, 39, 42,		0,65	-0,11-1,41	
	46-50, 57]	1116			0,09
Role functioning	[25, 29, 39, 42,		0,63	0,05-1,22	
	46-50, 57]	1116			0,04
Emotional functioning	[25, 29, 39, 42,		0,52	-0,10-1,13	
	46-50, 57]	1116			0,1
Cognitive functioning	[25, 29, 39, 42,		0,46	-0,21-1,13	
	47-50, 57]	779			0,18
Social functioning	[25, 29, 39, 42,		0,62	0,22-1,03	
	47-50, 57]	779			0,002
Fatigue	[25, 29, 39, 42,		-0,79	-1,66-0,08	
	47-50, 57]	779			0,08
Nausea/Vomitting	[25, 29, 39, 42,		-0,55	-1-(-0,1)	
	45-50, 57]	1247			0,02
Pain	[25, 29, 39, 42,		-0,86	-1,54-(-0,18)	
	46-50, 57]	1116			0,01
Dyspnea	[25, 29, 39, 42,		-0,37	-0,65-(-0,09)	
	47-50, 57]	779			0,009
Insomnia	[25, 29, 39, 42,		-0,54	-1,23-0,14	
	45-50, 57]	1247			0,12
Appetite loss	[25, 29, 39, 42,		-0,62	-1,29-0,05	
	45-50, 57]	1247			0,07

Constipation	[25, 29, 39, 42,		-0,14	-0,41-0,13	
	47-50, 57]	779			0,31
Diarrhea	[25, 29, 39, 42,		-0,43	-0,86-0,01	
	47-50, 57]	779			0,05
Financial difficulties	[25, 29, 39, 47-		-0,69	-1,21-(-0,16)	
	50, 57]	713			0,01

Tab. 3

	N studies	Effect				
		Sizes		Heterogeneity		
Moderator		SMD*	95% Cls	l <sup>2</sup>	z-score	p value <= <sup>\$</sup>
Risk of Bias status						
High	22	0.66	0.41-0.90	75.5	5.2	0.001
Low	1	0.84	0.62-1.1	0	7.4	0.001
Some	7	0.56	0.12-1.0	93.7	2.5	0.014
Blinding						
Yes	3	0.96	0.30-1.62	77.4	2.9	0.041
No	27	0.61	0.39-0.82	85.3	5.4	0.001
Randomized						
Yes	25	0.70	0.47-0.93	86.3	6.0	0.001
No	5	0.38	-0.09-0.85	63.4	1.58	0.11
Additional Treatment						
Chemotherapy	7	0.41	0.05-0.76	89.3	2.2	0.025
No add. Treatment	4	0.77	0.20-1.34	64.6	2.6	0.008
Individual best care	1	2.33	1.93-3.38	0	5.2	0.001
Conventional	16	0.58	0.36-0.81	66.2	5.1	0.001
Surgery	2	0.62	0.40-0.83	0	5.5	0.001
Controls						
Active	8	0.60	0.20-1.01	81.4	2.9	0.004
					2.5	
No active	22	0.65	0.41-0.90	85.9		0.001
Cancer type						
Lung cancer	3	-0.18	-0.41-0.06	0	1.45	0.15
Breast cancer	10	0.48	0.29-0.68	50	4.83	0.00001
Product						

	Abnova V.	2	1.06	0.07-2.04	86.5	2.1	0.036
	Eurixor	4	0.94	0.32-1.60	87.7	3.0	0.003
	Helixor	3	0.35	0.13-0.57	0	3.1	0.002
	Iscador	17	0.58	0.28-0.87	88.6	3.8	0.001
	Lektinol	2	0.67	-0.13-1.48	63.4	1.6	0.1
	Other	2	0.67	0.26-1.09	0	3.2	0.001
	Country						
	Germany	19	0.64	0.38-0.90	80.5	4.8	0.001
	Other	11	0.64	0.30-0.98	89.4	3.7	0.001
	Sponsoring						
	Corporate	10	0.49	0.11-0.87	92.0	2.5	0.011
	Public	3	0.64	-0.05-1.33	91.1	1.8	0.07
	Mixed	10	0.73	0.36-1.1	35.2	3.8	0.001
	No Information	7	0.73	0.27-1.19	82.8	3.1	0.002
	Type of Measure						
	Index <sup>1</sup>	6	0.33	-0.12-0.78	50.1	1.4	0.1
	Scale <sup>2</sup>	14	0.71	0.41-1.0	90.9	4.6	0.001
	Self Regulation <sup>3</sup>	10	0.73	0.39-1.07	35.2	4.1	0.001
- 1		ı		1	1		ı I

<sup>\*</sup>if heterogeneity > 25 random effects SMDs are given, else fixed effect

\$ two-tailed

1 Karnofsky Index, ECOG, Spitzer QoL

2 EORTC QoL Q30, FACT, GLQ-8

3 Grossarth-Maticek's self-regulation scale

Tab. 4

Moderator	Point estimate	95% Cls	z-score	p value <=
Study Year				Model: p = 0.0001
Slope	0.026	0.012-0.04	3.8	0.001

Age					Model: p = 0.3
Slope	-0.006	-0.02-0.006	-1.05	0.2	
Duration of Treatment					Model: p = 0.06
Slope	0.04	-0.0003-0.008	1.8	0.07	